home genetic news bioinformatics biotechnology literature journals ethics positions events sitemap


UBBFriend: Email This Page to Someone!
  HUM-MOLGEN
  Open Topic Forum
  pharmacognetics tests

Post New Topic  Post A Reply
profile | register | preferences | faq | search

next newest topic | next oldest topic
Author Topic:   pharmacognetics tests
marco_rossso
unregistered
posted 09-01-2003 10:19 AM           Edit/Delete Message Reply w/Quote
Ciao,

Many times it has been announced that pharmacognetics tests would be available.
Then it has periodically delayed. Do you think that these tests will be soon available
or that some more time will be necessary?

Best Regards,

Marco

IP: 151.36.191.61

luisasss
unregistered
posted 09-01-2003 04:35 PM           Edit/Delete Message Reply w/Quote
Hi,

As far as I have understood these test give a "probabilistic" and on "deterministic" information.
In other these tests tell thay a person is likely to have collateral effects getting a medicine.
From this result the decision of taking or not a drug is not automatic.
It depends on the other existing drugs, of the gravity of the illness, of the risk of the collateral effects.
Then it will be to the doctor and the patient to decide what to do.

So i think the main issue is the ooportunity or the difficulty to manage the information produced by it overcome the potential interest of it.

What do you think about it?

Luisa

IP: 151.36.191.61

giovanni_estrullo
Member
posted 09-02-2003 08:09 PM     Click Here to See the Profile for giovanni_estrullo   Click Here to Email giovanni_estrullo     Edit/Delete Message Reply w/Quote
Hi,
To stay on the pharmacogenetics topic ...
We have around 30.000 genes and at least 3000.000 proteines. A gene sintesise more than one proteine. In other words it is involved in more than one process of our body. For instance a gene cab be involved in more than one illness. For instance the gene involved in the answer to a medicine can be involved in other illnesses. For instance, the gene CETP shape the answer to the Statine uses in the treatment of arteriosclerosis, but also condition the evolution speed of the illness. In this case the "information" is positive because the patients for which the drug do not work are the same for which the illness evolve in a slower way. BUt if it was the contrary? In some cases, the information generated by a pharmacogenetic test will not only be on the answer to a drug but also to the susceptibility to a drug?

How do you think we should manage this information? do you think it is good to know or good to know only if there are some therapeutical decisions to be made?

IP: 151.38.159.156

All times are ET (US)

next newest topic | next oldest topic

Administrative Options: Close Topic | Archive/Move | Delete Topic
Post New Topic  Post A Reply
Hop to:

Contact Us | HUM-MOLGEN

Copyright by HUM-MOLGEN 1995-2015

Powered by: Ultimate Bulletin Board, Version 5.44a
© Infopop Corporation (formerly Madrona Park, Inc.), 1998 - 2000.